(R)-tert-butyl 4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate | 947275-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (R)-tert-butyl 4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate
• 英文别名: 1-Piperazinecarboxylic acid, 2-(2-hydroxyethyl)-4-(phenylmethyl)-, 1,1-dimethylethyl ester, (2R)-；tert-butyl (2R)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate
• CAS: 947275-35-6
• 化学式: C₁₈H₂₈N₂O₃
• 分子量: 320.432
• InChiKey: YYTFROGXRPOCQX-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate 在 palladium hydroxide carbon 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以to give the object compound (9.44 g) as an oil的产率得到(R)-tert-butyl 2-(2-hydroxyethyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Substituted imidazole compound and use thereof

  摘要：

  本发明涉及一种由以下式表示的化合物：其中每个符号如描述中所定义，或其盐或前药。本发明的化合物具有优越的肾素抑制活性，因此可用作预防或治疗高血压、高血压引起的各种器官损伤等的药物。

  公开号：

  US20090156612A1
• 作为产物：
  描述：

  N-苄基甘氨酸乙酯 在 lithium aluminium tetrahydride 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 73.0h， 生成 (R)-tert-butyl 4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate
  参考文献：
  名称：

  重要的5-HT 2C激动剂前体（R）-4-卤代-6,6a，7,8,9,10-六氢-5 H-吡嗪并[1,2- a ] [1，n ]萘啶的不对称合成

  摘要：

  N保护的（R）-4-卤代-6,6a，7,8,9,10-六氢-5 H-吡嗪并[1,2- a ] [1，n ]萘啶的不对称合成物描述了高效和选择性5-HT 2C激动剂的合成。关键的转化涉及N保护的双环氨基磺酸酯（R）-六氢-3 H-吡嗪并[1,2- c ] [1,2,3]恶二嗪1,1-二氧化物与（4-卤代-2-氟吡啶-3-基锂或（3-溴-5-氟吡啶-4-基）锂。原位的所得的氨基磺酸和随后分子内芳香族亲核取代反应（S水解Ñ AR）产生对映纯的三轮车。两步过程代表了四氢萘啶立体选择性合成的新方法。

  DOI：

  10.1016/j.tetlet.2018.04.030

文献信息

• [EN] HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS<br/>[FR] HEXAHYDROPYRAZINOBENZ- OU -PYRIDO-OXAZÉPINES TRANSPORTANT UN SUBSTITUANT CONTENANT DE L'OXYGÈNE ET SON UTILISATION POUR LE TRAITEMENT D'AFFECTIONS CONDITIONNÉES PAR 5-HT2C
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2017089458A1

  公开（公告）日：2017-06-01

  The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

  本发明涉及通式(I)的化合物，其中变量如权利要求和说明书中所定义。本发明还涉及含有此类化合物的药物组合物，涉及它们作为调节剂，特别是5-HT2C受体的激动剂或部分激动剂的使用，涉及它们用于制备预防或治疗对5-HT2C受体调节有反应的病症和疾病的药物，以及涉及预防或治疗对5-HT2C受体调节有反应的病症和疾病的方法。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DES RÉCEPTEURS 5-HT2C, COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2018035477A1

  公开（公告）日：2018-02-22

  The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.

  本发明涉及式A的化合物及其药物组合物，可调节5-HT2C受体的活性。本发明的化合物及其药物组合物用于治疗5-HT2C受体介导的疾病，如体重管理、诱发饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾等，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停症。还提供含有本文中化合物的组合物，可选择性地与辅助剂组合使用。
• Complementary asymmetric routes to fused tricyclic (R)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolines and (R)-1,2,3,4,5,5a,6,7-octahydro-[1,4]diazepino[1,2-a]quinolines
  作者：Thomas O. Schrader、Michelle Kasem、Qi Sun、Chunrui Wu、Albert Ren、Graeme Semple

  DOI：10.1016/j.tetlet.2016.09.025

  日期：2016.10

  7-octahydro-[1,4]diazepino[1,2-a]quinolines, low MW tricyclic organic scaffolds with a high degree of molecular complexity, are described. The key transformation in route 1 is the lateral lithiation of an N-Boc-o-toluidine and dianion trap with (S)-tert-butyldimethyl(oxiran-2-ylmethoxy)silane. An intramolecular SN2 cyclization then forms the optically pure tetrahydroquinoline core. Route 2 involves the

  （R）-2,3,4,4a，5,6-hexahydro-1 H -pyrazino [1,2- a ]喹啉和（R）-1,2,3,4,5的两种不同的对映选择性方法描述了5a，6，7-八氢-[1，4]二氮杂[1,2- a ]喹啉，其具有高度分子复杂性的低MW三环有机支架。路线1中的关键转变是N- Boc-邻甲苯胺和二价离子阱与（S）-叔丁基二甲基（环氧乙烷-2-基甲氧基）硅烷的侧向锂化反应。分子内小号Ñ 2环化然后形成光学纯的四氢喹啉核。路线2涉及（R）-2-（4-苄基-1-（Boc）哌嗪-2-基）乙醛或（R）-2-（4-苄基-1-（Boc）-1,4-二氮杂-2-基）乙醛与芳基锂和随后的分子内S N Ar反应形成三环。两种合成途径对于制备和鉴定靶向中枢神经系统（CNS）中表达的GPCR的配体都是有价值的。
• Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
  申请人：Kuroita Takanobu

  公开号：US20100121048A1

  公开（公告）日：2010-05-13

  The present invention relates to a compound represented by the formula: (I) wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent (s); U, V and W are each independently C or N, provided that when any one of U, V and W is N, then the others should be C; Ra and Rb are each independently a cyclic group optionally having substituent(s), a C 1-10 alkyl group optionally having substituent(s), a C 2-10 alkenyl group optionally having substituent(s), or a C 2-10 alkynyl group optionally having substituent(s); X is a bond, or a spacer having 1 to 6 atoms in the main chain; Y is a spacer having 1 to 6 atoms in the main chain; Rc is a hydrocarbon group optionally containing heteroatom(s) as the constituting atom(s), which optionally has substituent(s); m and n are each independently 1 or 2; and ring B optionally further has substituent(s), or a salt thereof. The compound of the present invention has excellent renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension, and the like.

  本发明涉及一种由式(I)表示的化合物：其中，环A是一种5或6成员的芳香杂环，可选地具有取代基；U、V和W分别独立地为C或N，但当U、V和W中的任何一个为N时，其他的应为C；Ra和Rb分别独立地为一个环状基团，可选地具有取代基；一个C1-10烷基，可选地具有取代基；一个C2-10烯基，可选地具有取代基；或一个C2-10炔基，可选地具有取代基；X是一条键或具有1到6个原子的主链间隔；Y是具有1到6个原子的主链间隔；Rc是一个含有杂原子作为构成原子的碳氢基团，可选地具有取代基；m和n分别独立地为1或2；环B可选地具有取代基，或其盐。本发明的化合物具有优异的肾素抑制活性，因此可用作预防或治疗高血压、高血压引起的各种器官损伤等的药物。
• 5-HT2C receptor agonists and compositions and methods of use
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10836764B2

  公开（公告）日：2020-11-17

  The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.

  本发明涉及调节 5-HT2C 受体活性的式 A 化合物及其药物组合物。本发明的化合物及其药物组合物用于治疗 5-HT2C 受体介导的疾病，如体重管理、诱导饱腹感和减少食物摄入量，以及预防和治疗肥胖症、抗精神病药诱导的体重增加、2 型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾等、强迫症谱系障碍和冲动控制障碍（包括咬指甲和嗜食）、睡眠障碍、尿失禁、精神障碍（包括精神分裂症、神经性厌食症和神经性贪食症）、老年痴呆症、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物诱发的运动障碍）、高血压、血脂异常、非酒精性脂肪肝、肥胖相关性肾病和睡眠呼吸暂停。此外，还提供了包含本文所述化合物的组合物，可选择与补充剂结合使用。